Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on immunology therapies for chronic diseases, will participate in key investor and industry conferences. Upcoming events include the B. Riley Securities' Neuro & Ophthalmology Conference (April 27-28), where CEO Daniel Vitt will speak, and the Outsourcing in Clinical Trials Europe (May 4-5) in Barcelona. Additionally, the company will present at Bio€quity Europe (May 16-18 and May 23-24) and attend the Digestive Disease Week (May 21-24) in San Diego. Details of the events and presentations can be found on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX) announced the promotion of Glenn Whaley, CPA, to the role of Chief Financial Officer, effective immediately. Whaley, who joined Immunic in 2019 and has held various finance roles, is recognized for his expertise and contributions to the company's financial operations. The CEO, Daniel Vitt, expressed confidence in Whaley's leadership as the company prepares for crucial data readouts from its lead product candidates, vidofludimus calcium and IMU-935, expected later this year. The company focuses on developing therapies for chronic inflammatory diseases.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on immunology therapies, will participate in several key conferences in March 2022. Notably, Duane Nash, Chairman of the Board, will engage in a fireside chat at the 34th Annual Roth Conference on March 15 in Dana Point, CA. Other conferences include Clinical Trial Supply Europe in Madrid and the American Academy of Dermatology Annual Meeting in Boston. The company's lead drug, IMU-838, targets autoimmune diseases. For updates, visit www.imux.com.
Immunic, Inc. (Nasdaq: IMUX) released its fourth quarter and full year 2021 financial results, reporting a net loss of $92.9 million, or $3.93 per share, up from a loss of $44.0 million, or $2.81 per share in 2020. Cash and cash equivalents stood at $86.9 million as of December 31, 2021. The company highlighted significant clinical progress, including enrollment completion in a Phase 2 trial for vidofludimus calcium in ulcerative colitis and initiation of a Phase 1 trial for IMU-935 in metastatic prostate cancer. Upcoming data readouts and patent allowances for IMU-935 through 2038 are also noted.
Immunic, Inc. (Nasdaq: IMUX) has announced the presentation of preclinical data on vidofludimus calcium (IMU-838), a selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis Organization (ECCO). The data showcases its potent anti-inflammatory activity. Key insights reveal the drug's effectiveness in managing immune responses and its potential as a combination treatment for ulcerative colitis. The company also disclosed blinded baseline characteristics of its phase 2 CALDOSE-1 trial, which enrolled 263 patients, with initial data expected in June 2022.
Immunic (Nasdaq: IMUX) will announce its financial results for Q4 and the year ended December 31, 2021, on February 24, 2022, before U.S. market opens. Following this, a webcast will be held at 8:00 am ET. The company focuses on developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis. This upcoming report may provide insights into the company's financial position and future strategy.
Immunic, Inc. (Nasdaq: IMUX) announced its participation in key investor and scientific conferences in February 2022. Notably, CEO Daniel Vitt will engage in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17 at 12:00 pm ET. Additionally, Dr. Evelyn Peelen will present preclinical data on IMU-838 at the 17th Congress of ECCO from February 16-19. A company overview will also be presented at the Aegis Capital Corp. Virtual Conference on February 23 at 11:30 am ET. Webcasts and presentations will be available on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX) announced a Notice of Allowance from the USPTO for patent application 16/644581 covering its oral IL-17 inhibitor, IMU-935, which has shown positive Phase 1 trial results. Additional patent allowances were received in Europe and Australia, providing market protection until at least 2038. IMU-935 aims to treat autoimmune diseases and has shown a differentiated safety profile. Ongoing trials also target moderate-to-severe psoriasis and metastatic castration-resistant prostate cancer, with expectations for initial data release soon.
On December 14, 2021, Immunic announced positive results from its Phase 1 clinical trial of IMU-935, a selective oral IL-17 inhibitor. The trial demonstrated favorable safety, tolerability, and pharmacokinetic (PK) profiles in healthy subjects during both single and multiple ascending dose phases. Key findings included a stable plasma concentration, no serious adverse events, and well-tolerated doses. The company plans to initiate Part C of the trial with moderate-to-severe psoriasis patients. These results support IMU-935's potential as a best-in-class treatment for autoimmune diseases.
Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patient in an open-label phase 1 trial for IMU-935, a selective inverse agonist targeting metastatic castration-resistant prostate cancer (mCRPC). Approved by UK regulatory bodies, the trial aims to evaluate safety, tolerability, and anti-tumor activity in 18-24 patients over three cycles. Initial clinical data is anticipated in Q3 2022. Preclinical data suggests IMU-935 could suppress drivers of CRPC, highlighting its potential as a treatment option for this challenging cancer.